108 related articles for article (PubMed ID: 38733396)
1. Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
Tölle M; Gökbuget N; Habringer S; Keller U; Schwartz S
Ann Hematol; 2024 May; ():. PubMed ID: 38733396
[No Abstract] [Full Text] [Related]
2. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
3. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
4. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
5. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
[TBL] [Abstract][Full Text] [Related]
6. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
9. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
10. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
11. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA
J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece.
Gourzoulidis G; Koulentaki M; Kattamis A; Bouzani M; Giatra C; Chotzagiannoglou V; Beletsi A; Kourlaba G
Clin Drug Investig; 2022 Nov; 42(11):999-1008. PubMed ID: 36227415
[TBL] [Abstract][Full Text] [Related]
13. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
[TBL] [Abstract][Full Text] [Related]
14. Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
Dunn KA; Forbrigger Z; Connors J; Rahman M; Cohen A; Van Limbergen J; Langille MGI; Stadnyk AW; Bielawski JP; Penny SL; MacDonald T; Kulkarni K
Leuk Lymphoma; 2021 Dec; 62(13):3244-3255. PubMed ID: 34279176
[TBL] [Abstract][Full Text] [Related]
15. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
[TBL] [Abstract][Full Text] [Related]
16. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
Hoshitsuki K; Zhou Y; Miller AM; Choi JK; Swanson HD; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Mullighan CG; Cheng C; Yang JJ; Relling MV; Pui CH; Inaba H
Leukemia; 2023 Sep; 37(9):1782-1791. PubMed ID: 37543655
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine.
Lu G; Karur V; Herrington JD; Walker MG
Proc (Bayl Univ Med Cent); 2016 Jan; 29(1):46-7. PubMed ID: 26722167
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review.
Bender C; Maese L; Carter-Febres M; Verma A
Blood Lymphat Cancer; 2021; 11():25-40. PubMed ID: 33907490
[TBL] [Abstract][Full Text] [Related]
19. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
[TBL] [Abstract][Full Text] [Related]
20. Adverse events associated with Pegaspargase biosimilar in pediatric patients with acute lymphoblastic leukemia: A prospective single-center study.
Panda BK; Gaikwad M; Bafna V; Vaidya N; Aundhe V; Mhatre A
J Oncol Pharm Pract; 2023 Jul; ():10781552231190827. PubMed ID: 37501538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]